Dr Alexis Willett, Policy Manager at Breakthrough Breast Cancer, says: "This research shows that the vast majority of breast cancer specialists surveyed were confident that patients in their breast units and who could benefit from Aromatase Inhibitors (AIs) were receiving them in line with NICE guidance. However, it's vital that this is backed up by formal audits to ensure that all patients receive the best treatments for them.
More...